Marsha Crochiere

Dedicated scientist, devoted wife and super-mom of three kids skillfully navigating the realm of work-life integration.

[Society for Immunotherapy of Cancer @sitcancer]

Are you at The CheckPoints at the Marriott Marquis tonight? Stop by our photo booth, sponsored by @PyxisOncology, and get a photo of your #SITC23 experience!

[Vigeo Therapeutics @vigeotx]

The @vigeotx research team is hiring! Come and join a dynamic and collaborative organization.
https://t.co/auzrMzRSh6

[Vigeo Therapeutics @vigeotx]

Is TSP-1 the natural enemy of Glioblastoma? Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately? #CD36 #CD47 #TSP1 #GBM #TME #immunooncology https://t.co/u10maSuft6 #mdpiijms via @IJMS_MDPI

[Vigeo Therapeutics @vigeotx]

Vigeo Therapeutics is excited to announce our inclusion in the AGILE Ph2-3 registrational study for glioblastoma with @GCAResearch #CD47 #GBM #TME #oncology https://t.co/dJwnmQu6ZM

[Vigeo Therapeutics @vigeotx]

Vigeo Therapeutics is excited to be joining the AGILE Phase 2-3 study for patients with newly diagnosed and recurrent GBM #CD36 #CD47 #oncology https://t.co/QxG7JlSlK4

[Vigeo Therapeutics @vigeotx]

Thank you for the hard work by the @vigeotx team to bring this poster of our GBM data to #SNO2021 meeting in Boston last week #CD47 #CD36 #immunooncology https://t.co/B66VGAyK8x

[Vigeo Therapeutics @vigeotx]

This week we are presenting new data at SNO’s annual meeting from our Ph1/2 expansion study evaluating the single-agent activity of VT1021 in subjects with recurrent glioblastoma. More details here: https://t.co/9Z3ODvjDqW
@NeuroOnc #CD47 #CD46 #ImmunoOncology

[Vigeo Therapeutics @vigeotx]

This week we are presenting new data at SITC's annual meeting from our Ph 1/2 study evaluating the single-agent activity of VT1021 in subjects with pancreatic cancer and recurrent glioblastoma. More details here:https://t.co/kOWLlZj4Ku
@sitcancer #CD47 #CD46 #ImmunoOncology

[Vigeo Therapeutics @vigeotx]

Next month we will be presenting new Phase 1/2 data from our pancreatic cancer expansion study at the Society for Immunotherapy of Cancer’s 2021 Annual Meeting. More details here: https://t.co/s5mDq9Qm6x
@sitcancer
#CD47
#CD46
#ImmunoOncology

[Vigeo Therapeutics @vigeotx]

Read the latest clinical update on VT1021, a first-in-class, dual-modulating compound that blocks the #CD47 immune checkpoint and activates #CD36
and hear from our new CEO, Jim Mahoney. See full press release here: https://t.co/f5wgoxlttq
#ImmunoOncology

[Vigeo Therapeutics @vigeotx]

Vigeo is hiring to support our expanding programs! Come and join our growing team #Immunooncology #oncology

https://t.co/tCPE5BlOkP

[Vigeo Therapeutics @vigeotx]

The Vigeo biomarker team is hiring! #CD36 #CD47 #Immunology
https://t.co/aFBM95aEO1

[Michael Cieslewicz @michaelc65]

Great opportunity at @vigeotx for #IHC experts.

[Vigeo Therapeutics @vigeotx]

Vigeo is hiring to build out our biomarker capabilities! #CD36 #CD47 #Oncology #Immunooncology https://t.co/0I6aTOPn8B

[Vigeo Therapeutics @vigeotx]

Vigeo is looking for motivated clin ops personnel to join our innovative company https://t.co/Jd4d8PlGem

[Vigeo Therapeutics @vigeotx]

Vigeo Therapeutics is looking for enthusiastic scientists to join our research team. https://t.co/auzrMzRSh6